Atrion (NASDAQ:ATRI) Downgraded by StockNews.com

StockNews.com downgraded shares of Atrion (NASDAQ:ATRI) from a hold rating to a sell rating in a research report released on Monday.

Atrion Stock Up 4.7 %

Shares of NASDAQ:ATRI opened at $424.19 on Monday. The company has a market cap of $746.57 million, a PE ratio of 38.46 and a beta of 0.60. The company’s 50-day moving average price is $402.59 and its 200 day moving average price is $364.60. Atrion has a fifty-two week low of $274.98 and a fifty-two week high of $643.48.

Atrion (NASDAQ:ATRI) last issued its quarterly earnings data on Thursday, February 29th. The medical instruments supplier reported $3.65 earnings per share for the quarter. The firm had revenue of $43.58 million for the quarter. Atrion had a net margin of 11.46% and a return on equity of 8.07%.

Atrion Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Friday, March 29th. Shareholders of record on Friday, March 15th were paid a dividend of $2.20 per share. The ex-dividend date was Thursday, March 14th. This represents a $8.80 annualized dividend and a yield of 2.07%. Atrion’s payout ratio is 79.78%.

Hedge Funds Weigh In On Atrion

Several large investors have recently bought and sold shares of the stock. Copeland Capital Management LLC grew its stake in shares of Atrion by 56.4% in the 4th quarter. Copeland Capital Management LLC now owns 86 shares of the medical instruments supplier’s stock worth $33,000 after purchasing an additional 31 shares during the last quarter. Harbor Investment Advisory LLC grew its stake in shares of Atrion by 33.1% in the 4th quarter. Harbor Investment Advisory LLC now owns 189 shares of the medical instruments supplier’s stock worth $72,000 after purchasing an additional 47 shares during the last quarter. Quadrant Capital Group LLC acquired a new position in shares of Atrion in the 4th quarter worth approximately $36,000. Bank of New York Mellon Corp grew its stake in shares of Atrion by 2.0% in the 3rd quarter. Bank of New York Mellon Corp now owns 10,006 shares of the medical instruments supplier’s stock worth $4,134,000 after purchasing an additional 194 shares during the last quarter. Finally, Tower Research Capital LLC TRC grew its stake in shares of Atrion by 592.3% in the 4th quarter. Tower Research Capital LLC TRC now owns 270 shares of the medical instruments supplier’s stock worth $102,000 after purchasing an additional 231 shares during the last quarter. Institutional investors and hedge funds own 66.19% of the company’s stock.

Atrion Company Profile

Atrion Corporation, together with its subsidiaries, develops, manufactures, and sells products for fluid delivery, cardiovascular, and ophthalmic applications in the United States, Canada, Europe, and internationally. The company's fluid delivery products include valves that fill, hold, and release controlled amounts of fluids or gasses for use in various intubation, intravenous, catheter, and other applications in the anesthesia and oncology fields, as well as promote infection control in hospital and home healthcare environments.